| Literature DB >> 32717916 |
Zhaoming Liu1, Yuchan Chen1, Saini Li1, Qinglin Wang2, Caiyun Hu1, Hongxin Liu1, Weimin Zhang1.
Abstract
The chemical investigation of a methanol extract of the deep-sea-derived fungus Diaporthe longicolla FS429 led to the isolation of two novel diterpenoids longidiacids A and B (1 and 2), two new polyketides (3 and 4), two new cytochalasin analogues longichalasins A and B (6 and 8) and three known analogues 5, 7, 9. Their structures were elucidated through comprehensive spectroscopic analysis, while the absolute configurations were established by the comparison of the experimental and quantum chemical calculated ECD spectra. The structure of compound 7 was confirmed through X-ray diffraction for the first time. In the bioassays compound 8 exhibited antiproliferative effects against SF-268, with an IC50 value of 16.44 μM. Moreover, compounds 1 and 8 were detected to inhibit 35.4% and 53.5% of enzyme activity of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) at a concentration of 50 μM.Entities:
Keywords: Diaporthe longicolla; bioactive metabolites; bioactivities; deep-sea derived-fungus
Mesh:
Substances:
Year: 2020 PMID: 32717916 PMCID: PMC7460381 DOI: 10.3390/md18080381
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of 1–9.
The 1H and 13C NMR data of 1 and 2.
| Position | 1 a | 2 a | ||
|---|---|---|---|---|
| 1 | 35.8, CH2 | 1.71, m | 35.4, CH2 | 1.83, m |
| 1.74, m | 1.80, m | |||
| 2 | 18.4, CH2 | 1.49, m | 18.2, CH2 | 1.58, m |
| 1.41, m | ||||
| 3 | 35.8, CH2 | 1.28, m | 34.9, CH2 | 1.33, m |
| 1.05, dd (13.5, 4.8) | 0.93, m | |||
| 4 | 37.0, C | 38.4, C | ||
| 5 | 51.9, CH | 1.40, m | 51.5, CH | 1.50, m |
| 6 | 19.0, CH2 | 1.82, dd (12.2, 5.9) | 18.8, CH2 | 1.76, m |
| 1.46, m | 1.44, m | |||
| 7 | 31.5, CH2 | 2.02, m | 31.1, CH2 | 2.02, m |
| 8 | 131.8, C | 128.7, C | ||
| 9 | 135.8, C | 138.8, C | ||
| 10 | 38.7, C | 38.6, C | ||
| 11 | 32.8, CH2 | 3.11, d (17.4) | 36.2, CH2 | 2.96, d (16.9) |
| 2.97, d (17.4) | 2.80, d (16.9) | |||
| 12 | 178.3, C | 179.9, C | ||
| 13 | 42.9, CH2 | 2.82, d (16.0) | 42.4, CH2 | 2.94, d (16.1) |
| 2.51, d (16.0) | 2.35, d (16.1) | |||
| 14 | 139.6, C | 136.5, C | ||
| 15 | 118.6, CH | 5.24, t (6.9) | 122.7, CH | 5.28, t (6.8) |
| 16 | 61.3, CH2 | 4.58, d (6.9) | 58.1, CH2 | 4.07, d (6.8) |
| 17 | 16.7, CH3 | 1.64, s | 15.4, CH3 | 1.60, s |
| 18 | 67.1, CH2 | 4.24, d (11.0) | 63.7, CH2 | 3.77, d (11.9) |
| 3.92, d (11.0) | 3.31, (overlap) | |||
| 19 | 27.1, CH3 | 0.99, s | 26.0, CH3 | 0.96, s |
| 20 | 20.5, CH3 | 0.99, s | 20.0, CH3 | 0.98, s |
| 21 | 171.5, C | |||
| 22 | 21.1, CH3 | 2.06, s | ||
| 23 | 171.3, C | |||
| 24 | 21.1, CH3 | 2.06, s | ||
a Recorded at 400 MHz (1H) and 100 MHz (13C) in CDCl3-d.
Figure 2COSY (blue bold lines) and key HMBC correlations (red arrows) of 1–4.
Figure 3Key NOESY correlations of 1 and 2.
Figure 4The calculated ECD spectra of 1/ent-1 at B3LYP/6-311+G(d,p) level and the experimental plot of 1/2.
The 1H and 13C NMR Data of 3 and 4.
| Position | 3 a | Position | 4 b | ||
|---|---|---|---|---|---|
| 1 | 37.0, C | 1 | 170.2, C | ||
| 2 | 161.3, C | 3 | 81.0, CH | 5.43, brd (3.1) | |
| 3 | 108.4, CH | 6.06, s | 3a | 150.6, C | |
| 4 | 176.9, C | 4 | 100.9, CH | 6.42, m | |
| 4a | 116.1, C | 5 | 165.4, C | ||
| 5 | 124.0, C | 6 | 102.5, CH | 6.32, d (1.8) | |
| 6 | 107.4, CH | 6.94, s | 7 | 158.2, C | |
| 7 | 148.9, C | 7a | 103.8, C | ||
| 8 | 134.9, C | 8 | 69.2, CH | 5.38, dq (3.1, 6.5) | |
| 8a | 144.3, C | 9 | 14.6, CH3 | 1.33, d (6.5) | |
| 9 | 123.8, CH | 6.18, dq (15.5, 1.7) | 10 | 170.1, C | |
| 10 | 137.2, CH | 6.93, dq (15.5, 6.9) | 11 | 19.3, CH3 | 1.89, s |
| 11 | 18.7, CH3 | 1.98, dd (6.9, 1.7) | |||
| 12 | 170.0, C | ||||
| 13 | 53.1, CH3 | 3.97, s | |||
| 14 | 56.8, CH3 | 4.01, s | - | ||
a Recorded at 400 MHz (1H) and 100 MHz (13C) in CDCl3-d; b Recorded at 400 MHz (1H) and 100 MHz (13C) in methanol-d4.
The 1H and 13C NMR data of 6 and 8.
| Position | 6 a | 8 a | ||
|---|---|---|---|---|
| 1 | 170.9, C | 174.1, C | ||
| 2 | - | 5.45, brs | - | - |
| 3 | 53.9, CH | 3.34, dt (9.8, 4.1) | 53.6, CH | 3.25, m |
| 4 | 43.3, CH | 3.07, t (4.1) | 50.6, CH | 2.13, d (5.3, 3.2) |
| 5 | 35.1, CH | 2.87, m | 32.6, CH | 2.80, m |
| 6 | 147.4, C | 147.2, C | ||
| 7 | 76.3, CH | 4.26, dd (12.4, 2.6) | 69.6, CH | 3.72, d (10.6) |
| 8 | 52.1, CH | 2.22, t (12.4) | 47.7, CH | 3.04, brt (10.1) |
| 9 | 59.7, C | 48.2, C | ||
| 10 | 45.2, CH2 | 2.95, dd (13.6, 4.1) | 45.5, CH2 | 2.84, dd (13.5, 4.9) |
| 2.58, dd (13.6, 9.8) | 2.70, dd (13.5, 9.6) | |||
| 11 | 14.6, CH3 | 1.18, d (6.7) | 13.5, CH3 | 0.98, d (6.7) |
| 12 | 114.5, CH2 | 5.39, brt (2.4) | 114.6, CH2 | 5.29, brs |
| 5.23, brt (2.5) | 5.10, brs | |||
| 13 | 44.4, CH | 2.43, dt (12.4, 9.8) | 130.4, CH | 6.02, dd (15.6, 9.6) |
| 14 | 87.3, CH | 3.70, ddd (12.4, 11.8, 3.1) | 137.2, CH | 5.72, ddd (15.6, 10.8, 4.8) |
| 15 | 39.8, CH2 | 2.01, dt (11.8, 3.1) | 42.9, CH2 | 2.24, m |
| 1.47, q (11.8) | 2.00, m | |||
| 16 | 30.3, CH | 2.13, m | 31.7, CH | 2.70, m |
| 17 | 133.3, CH | 5.27, brs | 136.0, CH | 5.26, brd (7.6) |
| 18 | 137.3, C | 132.5, C | ||
| 19 | 41.7, CH | 2.60, m | 136.1, CH | 6.67, d (16.4) |
| 20 | 43.3, CH2 | 3.47, dd (14.0, 12.4) | 120.4, CH | 5.61, dd (16.4, 3.7) |
| 2.73, dd (14.0, 5.1) | ||||
| 21 | 204.9, C | 78.1, CH | 5.48, m | |
| 22 | 24.5, CH3 | 1.13, d (7.2) | 24.0, CH3 | 1.05, d (6.9) |
| 23 | 23.4, CH3 | 1.76, s | 21.1, CH3 | 1.82, s |
| 1′ | 137.4, C | 137.4, C | ||
| 2′/6′ | 129.0, CH | 7.15, brd (6.80) | 129.1, CH | 7.15, m |
| 3′/5′ | 129.0, CH | 7.32, m | 128.9, CH | 7.32, m |
| 4′ | 127.1, CH | 7.25, m | 127.1, CH | 7.26, m |
a Recorded at 400 MHz (1H) and 100 MHz (13C) in CDCl3-d.
Figure 5X-ray diffraction analysis of compound 7.
Figure 6COSY (blue bold lines) and key HMBC correlations (red arrows) of 6 and 8.
Figure 7Key NOESY correlations of 6 and 8 (red and blue arrows implied the α- and β-orientation, respectively).
Figure 8The experimental ECD spectra of 6 and 7.
Cytotoxic Activity of the 1–9 against Different Human Cancer Cell Lines.
| Compounds | IC50 (µM) a | |||
|---|---|---|---|---|
| SF-268 | MCF-7 | HepG-2 | A549 | |
|
| >150 | >150 | >150 | >150 |
|
| >150 | >150 | >150 | >150 |
|
| >150 | >150 | >150 | >150 |
|
| 33.83 ± 2.43 | 88.95 ± 3.35 | 91.86 ± 8.74 | 88.25 ± 5.87 |
|
| >150 | >150 | >150 | >150 |
|
| 65.33 ± 1.59 | 73.48 ± 0.42 | 63.84 ± 2.73 | 64.00 ± 0.50 |
|
| 74.38 ± 6.24 | 79.55 ± 2.82 | 63.67 ± 1.25 | 70.29 ± 2.55 |
|
| 16.44 ± 0.75 | 36.45 ± 1.97 | 59.09 ± 1.30 | 33.34 ± 1.24 |
|
| 68.94 ± 2.15 | 91.91 ± 4.86 | 94.04 ± 2.56 | 84.52 ± 4.57 |
| Cisplatin b | 3.18 ± 0.04 | 2.78 ± 0.15 | 2.21 ± 0.02 | 1.49 ± 0.02 |
a Results are expressed as the mean ± standard error; b Positive control.